{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T20:31:40Z","timestamp":1772915500446,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1007\/s11102-006-9290-4","type":"journal-article","created":{"date-parts":[[2006,7,15]],"date-time":"2006-07-15T08:58:14Z","timestamp":1152953894000},"page":"151-154","source":"Crossref","is-referenced-by-count":27,"title":["Clinical and biochemical stabilization of Nelson\u2019s syndrome with long-term low-dose cabergoline treatment"],"prefix":"10.1007","volume":"9","author":[{"given":"Ilana","family":"Shraga-Slutzky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilan","family":"Shimon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Weinshtein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,7,15]]},"reference":[{"key":"9290_CR1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1046\/j.1365-2265.1998.00578.x","volume":"49","author":"MAA Pereira","year":"1998","unstructured":"Pereira MAA, Halpern A, Salgado LR, Mendonca BB, Nery M, Liberman B, Streeten DHP, Wajchenberg BL (1998) A study of patients with Nelson\u2019s syndrome. Clin Endocrinol 49:533\u2013539","journal-title":"Clin Endocrinol"},{"key":"9290_CR2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1530\/acta.0.1190435","volume":"119","author":"P Loli","year":"1988","unstructured":"Loli P, Berselli ME, Vignati F, De Granti C, Tagliaferi M (1988) Size reduction of an ACTH-secreting pituitary macroadenoma in Nelson\u2019s syndrome by sodium valproate: Effect of withdrawal and reinstitution of treatment. Acta Endocrinol 119:435\u2013442","journal-title":"Acta Endocrinol"},{"key":"9290_CR3","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1210\/jcem-56-5-985","volume":"56","author":"A Dornhorst","year":"1983","unstructured":"Dornhorst A, Jenkins JS, Lamberts SW, Abraham RR, Wynn V, Beckford U, Gillham B, Jones MT (1983) The evaluation of sodium valproate in the treatment of Nelson\u2019s syndrome. J Clin Endocrinol Metab 56:985\u2013991","journal-title":"J Clin Endocrinol Metab"},{"key":"9290_CR4","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1210\/jcem-43-5-1179","volume":"43","author":"DT Krieger","year":"1976","unstructured":"Krieger DT, Luria M (1976) Effectiveness of cyproheptadine in decreasing plasma ACTH concentrations in Nelson\u2019s syndrome. J Clin Endocrinol Metab 43:1179\u20131182","journal-title":"J Clin Endocrinol Metab"},{"key":"9290_CR5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2265.1990.tb00855.x","volume":"32","author":"HM Whitehead","year":"1990","unstructured":"Whitehead HM, Beacom R, Sheridan B, Atkinson AB (1990) The effect of cyproheptadine and \/or bromocriptine on plasma ACTH levels in patients cured of Cushing\u2019s disease by bilateral adrenalectomy. Clin Endocrinol 32:193\u2013201","journal-title":"Clin Endocrinol"},{"key":"9290_CR6","first-page":"514","volume":"82","author":"SWJ Lamberts","year":"1997","unstructured":"Lamberts SWJ, Klijn JGM, Quijada M, Timmermans HAT, Uitterlinden P, de Jong FH, Birkenhager JC (1997) The mechanism of the suppressive action of bromocriptine on adrenocorticotropin secretion in patients with Cushing\u2019s disease and Nelson\u2019s syndrome J Clin Endocrinol Metab 82:514\u2013517","journal-title":"J Clin Endocrinol Metab"},{"key":"9290_CR7","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1210\/edrv-14-4-443","volume":"14","author":"JW Miller","year":"1993","unstructured":"Miller JW, Crapo L (1993) The medical treatment of Cushing\u2019s syndrome. Endocr Rev 14:443\u2013458","journal-title":"Endocr Rev"},{"key":"9290_CR8","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1365-2265.2006.02501.x","volume":"64","author":"KR Mullan","year":"2006","unstructured":"Mullan KR, Leslie H, McCance DR, Sheridan B, Atkinson AB (2006) The PPAR-gamma activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson\u2019s syndrome. Clin Endocrinol 64:519\u2013522","journal-title":"Clin Endocrinol"},{"key":"9290_CR9","first-page":"300","volume":"62","author":"LA Casulari","year":"2004","unstructured":"Casulari LA, Naves L, Mello P, Neto AP, Papadia C (2004) Nelson\u2019s syndrome: Complete remission with cabergolone but not with bromocriptine or cyproheptadine treatment. Horm Res 62:300\u2013305","journal-title":"Horm Res"},{"key":"9290_CR10","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/BF03343660","volume":"22","author":"R Pivonello","year":"1999","unstructured":"Pivonello R, Faggiano A, Di Salle F, Filipella M, Lombardi G, Colao A (1999) Complete remission of Nelson\u2019s syndrome after 1-year treatment with cabergoline. J Endocrinol Invest 22:860\u2013865","journal-title":"J Endocrinol Invest"},{"key":"9290_CR11","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1507\/endocrj1954.39.385","volume":"39","author":"LB Mercado-Asis","year":"1992","unstructured":"Mercado-Asis LB, Yasuda K, Murayama M, Mune T, Morita H, Miura K (1992) Beneficial effects of high daily dose bromocriptine in Cushing\u2019s disease. Endocrinol Jpn 39:385\u2013395","journal-title":"Endocrinol Jpn"},{"key":"9290_CR12","first-page":"841","volume":"80","author":"AC Andreotti","year":"1995","unstructured":"Andreotti AC, Pianezzola E, Persiani S, Pacciarini MA, Strolin Bendetti M, Pontiroli AE (1995) Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0 and 1.5\u00a0mg) in healthy male volunteers. J Clin Endocrinol Metab 80:841\u2013845","journal-title":"J Clin Endocrinol Metab"},{"key":"9290_CR13","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1517\/14656566.1.3.555","volume":"1","author":"A Colao","year":"2000","unstructured":"Colao A, Lombardi G, Annunziato L (2000) Cabergoline. Expert Opin Pharmacother 1:555\u2013574","journal-title":"Expert Opin Pharmacother"},{"key":"9290_CR14","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM199410063311403","volume":"331","author":"J Webster","year":"1994","unstructured":"Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1994) for the Cabergoline Comparative Study Group. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 331:904\u2013909","journal-title":"N Engl J Med"},{"key":"9290_CR15","first-page":"76","volume":"53","author":"A Colao","year":"2000","unstructured":"Colao A, Di Sarno A, Marzullo P, Di Somma C, Cerbone G, Landi ML, Faggiano A, Merola B, Lombardi G (2000) New medical approaches in pituitary adenomas. Horm Res 53:76\u201387","journal-title":"Horm Res"},{"key":"9290_CR16","first-page":"1674","volume":"89","author":"Y Greenman","year":"2005","unstructured":"Greenman Y, Tordjiman K, Osher E, Veshchev I, Shenkerman G, Reider-Groswaaser H, Segev Y, Quaknine G, Stern N (2005) Postoperative treatment of clinically non-functioning pituitary adenomas with dopamine agonists decreases tumor remnant growth. Clin Endocrinol 89:1674\u20131683","journal-title":"Clin Endocrinol"},{"key":"9290_CR17","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1210\/jc.2003-030859","volume":"89","author":"R Pivonello","year":"2004","unstructured":"Pivonello R, Matrone, Filipella M, Cavallo LM, Di Somma C, Cappabianca P, Colao A, Annunziato A, Lombardi G (2004) Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: Comparison with effectiveness of cabergoline treatment. J Clin Endocrinol metab 89:1674\u20131683","journal-title":"J Clin Endocrinol metab"},{"key":"9290_CR18","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1210\/jc.2003-030837","volume":"89","author":"R Pivonello","year":"2004","unstructured":"Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ, Lamberts SW (2004) Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 89:2452\u20132462","journal-title":"J Clin Endocrinol Metab"},{"key":"9290_CR19","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1210\/jcem-69-3-500","volume":"69","author":"I Pellegrini","year":"1989","unstructured":"Pellegrini I, Rasolonjanahary R, Gunzg, Bertarnd P, Delivet S, Jedynak CP, Kordon C, Peilon F, Jaquet P, Enjalbert A (1989) Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 69;500\u2013509","journal-title":"J Clin Endocrinol Metab"},{"key":"9290_CR20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0889-8529(05)70064-5","volume":"28","author":"N Sonino","year":"1999","unstructured":"Sonino N, Boscaro M (1999) Medical therapy for Cushing\u2018s disease. Endocrinol Metab Clin North Am 28:211\u2013222","journal-title":"Endocrinol Metab Clin North Am"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-006-9290-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11102-006-9290-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-006-9290-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T14:13:23Z","timestamp":1559571203000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11102-006-9290-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["9290"],"URL":"https:\/\/doi.org\/10.1007\/s11102-006-9290-4","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}